Type segmentation distinguishes three principal product classifications within the S-adenosyl-L-methionine (SAMe) market: prescription pharmaceuticals, over‑the‑counter (OTC) formulations, and nutraceutical or functional‑food ingredients. Prescription SAMe is manufactured under stringent regulatory frameworks, targeting clinicians who prescribe it for severe depressive episodes or hepatic disorders; its pricing structure and reimbursement pathways generate the highest per‑unit revenue despite a relatively limited patient base. OTC SAMe, sold in pharmacies and health‑store aisles, benefits from self‑selection and broader consumer awareness, driving volume growth in regions with mature supplement markets. Nutraceutical SAMe is incorporated into fortified foods, beverages, and combination dietary supplements, leveraging synergistic formulations to capture market share in wellness‑focused channels. Each type contributes distinctively to overall market size: prescription accounts for roughly 35 % of total revenue, OTC for 45 %, and nutraceuticals for the remaining 20 %, reflecting divergent cost structures, distribution networks, and adoption dynamics. This typology underpins strategic investment decisions and informs regulatory risk assessments across the SAMe ecosystem.
